4% Tetrasodium EDTA to Prevent Central Venous Access Device–Associated Complications
JAMA · 2026
DOI: 10.1001/jama.2026.6025 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JAMA, 2026. Verfasst von Marlena Ornowska und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, British Columbia, Canada. Hauptthemen laut MEDLINE: Catheter Obstruction, Catheter-Related Infections, Catheterization, Central Venous, Central Venous Catheters. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Use of central venous access devices (CVADs) can result in catheter-associated bloodstream infection, catheter occlusion, and catheter-related venous thrombosis. EDTA is a potent anticoagulant, antimicrobial, and antibiofilm agent that can be instilled into inactive CVAD ports as a locking fluid to decrease the risk of infection and maintain patency.
Objective
To determine whether a 4% tetrasodium EDTA (t-EDTA) locking fluid reduces CVAD-associated infections, occlusions, and thrombolytic use in adults treated in an intensive care unit (ICU). Design, Setting, and Participants Pragmatic, triple-blind, multicenter, cluster-randomized crossover trial including patients older than 18 years in the ICU with a CVAD in place and at least 1 lumen not in use. The trial was conducted in 6 Canadian hospitals (3 community hospitals and 3 academic centers). The first patient was enrolled on March 22, 2022, and the date of last follow-up occurred on September 25, 2024.
Interventions
The ICUs were randomized to use prefilled, identical, masked syringes containing 2.5 mL of t-EDTA (intervention) or control locking fluid (saline or 4% citrate for hemodialysis lines) for all trial participants over a 3.5-month period. After a 1-month follow-up period, ICUs crossed over to the opposing treatment group for another 3.5 months, with a subsequent 1-month follow-up. Main Outcomes and Measures The primary outcome was a composite incidence rate of CVAD-associated bloodstream infection, catheter occlusion requiring alteplase use, and/or catheter removal due to occlusion. Three of the 8 prespecified secondary outcomes included incidence rates of each component of the primary outcome separately.
Results
Of the 1574 eligible patients, 1468 (mean age, 60 [SD, 16.0] years; 37.7% female) were included in the analysis (696 receiving t-EDTA and 772 receiving control). The incidence rate of primary outcome events was 13.1 per 1000 catheter-days (74 events) in the t-EDTA group vs 19.9 per 1000 catheter-days (126 events) in the control group. In adjusted multivariate analysis, the incidence rate of the composite outcome was lower among patients receiving t-EDTA vs control (rate ratio, 0.68; 95% CI, 0.47-0.96; P = .03). Among the 3 components of the primary outcome, only the secondary outcome of CVAD occlusion requiring administration of alteplase significantly differed between the groups, with lower rates in the t-EDTA group vs control (66 vs 112; incidence rate, 11.67 and 17.73 per 1000 catheter-days, respectively; rate ratio, 0.66; 95% CI, 0.46-0.96). Conclusions and Relevance Compared with control locking solution, use of 4% t-EDTA locking solution for CVADs reduced the incidence of a composite outcome of CVAD-associated bloodstream infection, catheter occlusion requiring alteplase use, and catheter removal due to occlusion among adult patients in the ICU. Trial Registration ClinicalTrials.gov Identifier: NCT04548713
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, British Columbia, Canada.
- Department of Critical Care, Royal Columbian Hospital, New Westminster, British Columbia, Canada.
- Fraser Health Authority, Surrey, British Columbia, Canada.
- University of British Columbia Centre for Advancing Health Outcomes, Providence Healthcare, Vancouver, British Columbia, Canada.
- School of Population and Public Health, University of British Columbia, Vancouver, Canada.
- Section of Critical Care, University of Manitoba, Winnipeg, Canada.
Zitieren
APA
Ornowska, M., Wittmann, J., Blitz, S., Wong, H., Vazquez-Grande, G., Mitra, A. R., Jang, W., Wood, G., Ovakim, D., Forrest, D., Rohrs, E., & Reynolds, S. (2026). 4% Tetrasodium EDTA to Prevent Central Venous Access Device–Associated Complications. JAMA. https://doi.org/10.1001/jama.2026.6025
Vancouver
Ornowska M, Wittmann J, Blitz S, Wong H, Vazquez-Grande G, Mitra AR, et al. 4% Tetrasodium EDTA to Prevent Central Venous Access Device–Associated Complications. JAMA. 2026. doi:10.1001/jama.2026.6025
BibTeX
@article{Ornowska2026,
author = {Ornowska, Marlena and Wittmann, Jessica and Blitz, Sandra and Wong, Hubert and Vazquez-Grande, Gloria and Mitra, Anish R and Jang, Wesley and Wood, Gordon and Ovakim, Daniel and Forrest, David and Rohrs, Elizabeth and Reynolds, Steven},
title = {4% Tetrasodium EDTA to Prevent Central Venous Access Device–Associated Complications},
journal = {JAMA},
year = {2026},
doi = {10.1001/jama.2026.6025}
}
EUVIMED